100,095 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Acquired by Jane Street Group LLC

Jane Street Group LLC bought a new stake in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 100,095 shares of the company's stock, valued at approximately $1,120,000. Jane Street Group LLC owned about 0.34% of NeuroPace at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NPCE. Geode Capital Management LLC lifted its holdings in NeuroPace by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock valued at $3,615,000 after purchasing an additional 5,781 shares in the last quarter. Northern Trust Corp lifted its stake in shares of NeuroPace by 15.7% during the 4th quarter. Northern Trust Corp now owns 184,847 shares of the company's stock valued at $2,068,000 after buying an additional 25,035 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of NeuroPace by 440.4% during the 4th quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company's stock valued at $725,000 after buying an additional 52,829 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in NeuroPace by 21.2% in the 4th quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company's stock worth $328,000 after buying an additional 5,133 shares during the period. Finally, Walleye Capital LLC purchased a new stake in NeuroPace in the 4th quarter worth $319,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Martha Morrell sold 78,334 shares of NeuroPace stock in a transaction on Friday, February 21st. The stock was sold at an average price of $13.72, for a total value of $1,074,742.48. Following the completion of the transaction, the insider now directly owns 81,993 shares in the company, valued at approximately $1,124,943.96. This trade represents a 48.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 168,136 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total transaction of $2,664,955.60. Following the completion of the sale, the insider now directly owns 3,238,199 shares in the company, valued at approximately $51,325,454.15. This trade represents a 4.94% decrease in their position. The disclosure for this sale can be found here. 22.20% of the stock is currently owned by corporate insiders.

NeuroPace Stock Up 0.8%

NASDAQ:NPCE opened at $18.13 on Thursday. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The company's 50 day moving average is $12.40 and its two-hundred day moving average is $11.79. NeuroPace, Inc. has a twelve month low of $5.45 and a twelve month high of $18.98. The company has a market cap of $594.65 million, a PE ratio of -18.13 and a beta of 2.04.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.05. The business had revenue of $22.52 million during the quarter, compared to analysts' expectations of $21.85 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. Analysts anticipate that NeuroPace, Inc. will post -1 EPS for the current year.

Analyst Upgrades and Downgrades

NPCE has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. Wells Fargo & Company raised their price objective on NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a research report on Thursday, January 30th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $17.00 target price on shares of NeuroPace in a report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.00.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

Want to see what other hedge funds are holding NPCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeuroPace, Inc. (NASDAQ:NPCE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.